Global medicines company Novartis selected the Salesforce Agentforce Life Sciences platform. The goal is to personalize customer engagement and unify interactions across marketing, sales, and patient services.
Novartis plans a global rollout of the platform over the next five years. The collaboration leverages Salesforce’s AI and data capabilities to create compliant healthcare touchpoints, helping deliver therapies to patients more effectively.
Investment firm BTIG initiated coverage with a Buy rating on the same day. BTIG cited Salesforce’s platform architecture and rapid innovation within the Agentforce layer as key factors. The Novartis deal validates this strategy, showcasing the adoption of specialized AI-driven platforms in key industries.